Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers provider‑administered Cinqair, Fasenra, and Nucala only for their specific FDA‑approved respiratory indications (severe eosinophilic asthma, EGPA, HES, CRSwNP, and Nucala for certain COPD patients) and excludes unproven uses (acute bronchospasm/status asthmaticus, certain vasculitides, organ- or life‑threatening EGPA, other non‑approved eosinophilic conditions) and concurrent use with other biologics for the same indication. Coverage requires documentation of diagnosis and clinical response, prescriber specialty, meeting age and eosinophil thresholds (e.g., severe asthma ≥150 cells/µL; Nucala‑HES ≥1000 cells/µL and disease ≥6 months), optimized prior therapy and specified prior‑trial/failure criteria (Cinqair may require prior failure/intolerance to Fasenra/Nucala and tezepelumab), no concomitant biologics, and time‑limited approvals with reauthorization based on demonstrated benefit (up to 12 months).

"Cinqair (reslizumab) — add-on maintenance therapy for severe asthma in adults (≥18 years) with an eosinophilic phenotype when criteria below are met."